Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Public ClinicalTrials.gov record NCT06265285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Study identification
- NCT ID
- NCT06265285
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 50 participants
Conditions and interventions
Conditions
- Advanced Esophageal Squamous Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Clinical Stage IIC Cutaneous Melanoma AJCC v8
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Esophageal Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Locally Advanced Urothelial Carcinoma
- Lung Non-Small Cell Carcinoma
- Malignant Solid Neoplasm
- Metastatic Colorectal Carcinoma
- Metastatic Cutaneous Melanoma
- Metastatic Esophageal Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Recurrent Esophageal Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Unresectable Cutaneous Melanoma
- Unresectable Esophageal Squamous Cell Carcinoma
- Unresectable Urothelial Carcinoma
- Urothelial Carcinoma
Interventions
- Home Health Encounter Other
- Nivolumab Biological
- Patient Monitoring Procedure
- Questionnaire Administration Other
Other · Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2024
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Dec 3, 2025
2024 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06265285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06265285 live on ClinicalTrials.gov.